CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6930 result(s)

vedolizumab (Entyvio)

Last Updated: August 10, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: vedolizumab
Indications: Crohn’s disease

  • Brand Name: Entyvio
  • Manufacturer: Takeda Canada Inc.
  • Project Number: SR0647-000
  • Project Status: Active
  • Submission Type: New

eculizumab (Soliris)

Last Updated: August 10, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: eculizumab
Indications: Neuromyelitis optica spectrum disorder

  • Brand Name: Soliris
  • Manufacturer: Alexion Pharma Canada Corp.
  • Project Number: SR0640-000
  • Project Status: Active
  • Submission Type: New

dapagliflozin (Forxiga )

Last Updated: August 10, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: dapagliflozin
Indications: Heart failure with reduced ejection fraction

  • Brand Name: Forxiga
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: SR0642-000
  • Project Status: Active
  • Submission Type: New

Halobetasol propionate and tazarotene (Duobrii)

Last Updated: August 10, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: Halobetasol propionate and tazarotene
Indications: Psoriasis, moderate to severe plaque

  • Brand Name: Duobrii
  • Manufacturer: Bausch Health, Canada Inc.
  • Project Number: SR0638-000
  • Project Status: Active
  • Submission Type: New

Developing a COVID-19 Vaccine

Event Date: August 12, 2020
Result type: Events

The COVID-19 pandemic has disrupted our lives. Medical experts around the globe have said that what we each have known as normal life won’t fully resume until we have a vaccine, and that could take years. In this webinar, an expert panel will take you inside the race to develop a COVID-19 vaccine. What’s involved in developing a vaccine? Why doe...

CADTH Weekly COVID-19 Update

Last Updated: August 10, 2020
Result type: Reports
Product Line: New at CADTH

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time. Our COVID-19 evidence portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and growing state of the international scientific evidence...

Marcel Saulnier

Published on: August 10, 2020
Result type: General Content

Member — Jurisdictional (Federal) Marcel Saulnier, Associate ADM, Strategic Policy Branch

apomorphine hydrochloride (Kynmobi)

Last Updated: August 5, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: apomorphine hydrochloride
Indications: Parkinson’s disease

  • Brand Name: Kynmobi
  • Manufacturer: Sunovion Pharmaceuticals Canada Inc.
  • Project Number: SR0650-000
  • Project Status: Active
  • Submission Type: New

siponimod (Mayzent)

Last Updated: August 5, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: siponimod
Indications: Secondary progressive multiple sclerosis

  • Brand Name: Mayzent
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0631-000
  • Project Status: Active
  • Submission Type: New